Skip to main content

Building

A better future

through education, skill development and research

LEARN MORE

Investigational Cream May Help Patients with Inflammatory Skin Disease

A study published in the British Journal of Dermatology indicates that an investigational nonsteroidal topical cream (PAC-14028) may be effective for treating atopic dermatitis, one of the most common inflammatory skin diseases.

Wednesday, January 9, 2019 12:01 am EST

A study published in the British Journal of Dermatology indicates that an investigational nonsteroidal topical cream (PAC-14028) may be effective for treating atopic dermatitis, one of the most common inflammatory skin diseases.

The trial involved a cream that blocks the transient receptor potential vanilloid subfamily, member 1, an ion channel involved in the perception of pain. This channel also contributes to inflammation and itchy skin in patients with atopic dermatitis.

In the 8-week, randomized, double-blind, multicentre, study that enrolled 194 adults with mild to moderate atopic dermatitis, the cream improved clinical symptoms and signs with a favourable safety profile.

According to the authors, a phase III clinical trial is underway to test if the topical medicine is safe and effective in teens and adults.

Additional Information

Link to Study: https://onlinelibrary.wiley.com/doi/full/10.1111/bjd.17455  

About Journal 

The BJD strives to publish the highest-quality dermatological research. In so doing, the Journal aims to advance the understanding, management and treatment of skin disease in order to improve the outcomes of patient care. The main focus of the BJD (described in a position statement published in the June 2015 issue) is to publish the highest-quality research encompassing the following:

  • Clinical trials that are registered before recruitment starts and report fully according to the CONSORT guidelines.
  • Clinical studies that include epidemiology, qualitative research and mixed methods that conform to the STROBE and SRQR reporting guidelines.
  • Translational research that describes basic and applied science of potential clinical relevance.
  • Systematic reviews following the PRISMA statement (http://www.prisma-statement.org/ ), MOOSE guidelines or the ENTREQ statement.

About Wiley

Wiley is a global leader in research and education. Our online scientific, technical, medical, and scholarly journals, and our digital learning, assessment, certification and student-lifecycle services and solutions help universities, academic societies, businesses, governments and individuals to achieve their academic and professional goals. For more than 200 years, we have delivered consistent performance to our stakeholders. The Company's website can be accessed at www.wiley.com.

Multimedia Files:

Preview image

Contact:

Josh Glickman +1 201-748-6572 (US)
Penny Smith +44 (0) 1243 770448 (UK)
newsroom@wiley.com

Business Wire NewsHQsm